4-butyrolactone has been researched along with Acute Myelogenous Leukemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dhaini, J; Haykal, T; Hodroj, MH; Rizk, S; Tannous, S | 1 |
| Chen, L; Dou, G; Jiang, M; Jiang, Z; Li, C; Li, L; Li, P; Liu, G; Lu, Q; Ma, H; Qi, H; Wang, C; Yang, Y | 1 |
2 other study(ies) available for 4-butyrolactone and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
The anti-cancer effect of flaxseed lignan derivatives on different acute myeloid leukemia cancer cells.
Topics: 4-Butyrolactone; Antineoplastic Agents, Phytogenic; Apoptosis; Butylene Glycols; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Child; Female; Flax; Glucosides; Humans; Leukemia, Myeloid, Acute; Lignans; Plant Extracts; Reactive Oxygen Species; Seeds | 2020 |
Z-Ligustilide Selectively Targets AML by Restoring Nuclear Receptors Nur77 and NOR-1-mediated Apoptosis and Differentiation.
Topics: 4-Butyrolactone; Animals; Apoptosis; Cell Differentiation; Humans; Leukemia, Myeloid, Acute; Membrane Transport Proteins; Mice; Mice, Inbred NOD; Mice, SCID; Nuclear Receptor Subfamily 4, Group A, Member 1 | 2021 |